US NIH forms an international alliance with major pharmaceutical companies across the world and international organizations to conduct rapid tests for COVID-19 drugs and vaccines
Fremont, CA: The US National Institutes of Health (NIH) is all set to release a public-private partnership that aims to bring together health agencies and pharmaceutical companies to kickstart research on COVID-19 drugs and vaccines.
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will focus on creating a strategic structure to prioritize vaccine and drug candidates. Furthermore, the engaging parties will assist in managing clinical trials and regulatory processes. Partner assets will be leveraged for quick response to the ongoing COVID-19 crisis and other future pandemics.
Along with NIH, health agencies that are participating in ACTIV comprise of the US Food and Drug Administration, Centers for Disease Control and Prevention, Health and Human Services Office of the Assistant Secretary for Preparedness and Response along with the European Medicines Agency. The Not-for-Profit organizations' Foundation of the NIH will also be participating in the alliance. These organizations will work in alignment with 16 other pharmaceutical companies, including Pfizer, AstraZeneca, Takeda, Johnson & Johnson, Vir Biotechnology, and GlaxoSmithKline, among others.
The members of ACTIV will offer infrastructure, subject matter expertise, funding to discover, prioritize, and enable the growth of specific promising candidates into clinical trials. The companies will also provide particular compounds that are prioritized as some have already passed different phases of development, along with the data support carried out for COVID-19 research. At present, researchers are working to collect more than 100 potential preventives, and therapeutics against COVID-19, pointed out NIH.
ACTIV partnership also intends to impart guidance for selective development of candidates as well as interlinking clinical trial networks for the rapid evaluation of new and repurposed candidates.
FDA Commissioner Stephen Hahn said: "Using the most advanced clinical trial methods to test multiple interventions rapidly will help get the answers we need as soon as possible to expedite potential prevention and treatment approaches to fight COVID-19.
"Collaboration is a critical ingredient for success, and the FDA will continue to use every tool possible under our Coronavirus Treatment Acceleration Program to speed the development of safe and effective medical countermeasures."
The primary aim of the partnership is to focus on standardizing and sharing preclinical assessment pathways in an open forum and accelerate the clinical study of drug candidates with a near term potential. The partners involved will maximize clinical trial capacity and effectiveness, along with advanced vaccine development.